Arsenic trioxide with chemo for relapsed medulloblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding arsenic trioxide to standard chemotherapy can help children whose medulloblastoma has come back or is hard to treat, especially if the tumor has certain genetic changes. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 months and 18 years old.
- Your tumor is a type called SHH-activated medulloblastoma that has come back after standard treatment or has not responded to two cycles of first-line chemo.
- Or, your tumor has a TP53 gene mutation (found through genetic testing), even if it is newly found during treatment.
- You have not had another cancer that was treated with chemo and radiation to the belly.
- You do not have severe heart, kidney, or liver problems.
- A parent or guardian must sign a consent form agreeing to the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
This trial tests adding atovaquone to standard radiation therapy for children with aggressive brain tumors like high-grade glioma (a fast-growing brain cancer) or medulloblastoma. The goal is to see if this drug, which targets energy production in cancer cells, can make radiation work better.
This trial tests a new medicine (RVU120) combined with an existing drug (everolimus) in children whose medulloblastoma (a type of brain tumor) has come back or gotten worse. The goal is to see if this combination can help stop the tumor from growing.
This trial tests two drugs, axitinib and etoposide, taken by mouth to treat children and young adults with medulloblastoma or ependymoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth.
This trial compares two standard treatment plans for young children with a specific type of medulloblastoma (a brain tumor). It looks at how each treatment affects thinking and learning over time, to see which one helps children do better in the long run.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.